An Evaluation of the Immunochemical Measurement of Prostatic Acid Phosphatase and Prostatic Specific Antigen in Carcinoma of the Prostate

1986 ◽  
Vol 12 (2) ◽  
pp. 123-130 ◽  
Author(s):  
J.K. Siddall ◽  
E.H. Cooper ◽  
D.W.W. Newling ◽  
M.R.G. Robinson ◽  
P. Whelan
Keyword(s):  
Acid Phosphatase ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Specific Antigen ◽  
Carcinoma Of The Prostate

Clinical Behaviour of Prostatic Specific Antigen and Prostatic Acid Phosphatase: A Comparative Study

1989 ◽  
Vol 4 (2) ◽  
pp. 87-94 ◽  
Author(s):  
J. Morote Robles ◽  
A. Ruibal Morell ◽  
J.A. De Torres Mateos ◽  
A. Soler Roselló
Keyword(s):  
Acid Phosphatase ◽  
False Positive ◽  
Normal Limit ◽  
Specific Antigen ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Prostatic Hypertrophy ◽  
Prostatic Specific Antigen ◽  
Positive Results

We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1383 patients using a double antibody radioimmunoassay (RIA) I125. Establishing the upper normal limit in 10 ng/ml PSA and 2.5 ng/ml for PAP, the false positive results were only 1.9 and 5.1 percent in men with non-prostatic benign or malignant pathology and respectively 0 and 2.2 percent in women. We detected false positive levels for these two tumoral markers in 3.5 and 4.7 percent of patients with non-complicated benign prostatic hypertrophy, 64.8 and 19.2 percent in complicated benign prostatic hypertrophy, 24 and 16 percent in acute prostatitis and 3.3 percent in chronic prostatitis. The sensitivity in patients with prostate cancer was 87.2 percent for PSA and 64.1 percent for PAP, and there was a better correlation with PSA than PAP for tumoral spread and histological grading. Finally, clinical efficacy was higher with PSA and was no better when both markers were assayed.

Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.

1986 ◽  
Vol 32 (11) ◽  
pp. 2040-2043 ◽  
Author(s):  
J K Siddall ◽  
S D Shetty ◽  
E H Cooper
Keyword(s):  
Acid Phosphatase ◽  
Disease Progression ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Carcinoma Of The Prostate ◽  
Normal Limits ◽  
Bony Metastases

Abstract We have compared the concentrations in serum of gamma-seminoprotein (gamma-SM) and prostate specific antigen (PSA), two antigens of prostatic origin that are synthesized independently of prostatic acid phosphatase (PAP, EC 3.1.3.2), to assess their potential in monitoring prostatic cancer. At presentation, 27/30 (90%) patients with metastases had a PSA concentration greater than 10 ng/mL, and 29/30 (97%) a gamma-SM concentration greater than 10 ng/mL; 21/61 (34%) with disease but without metastases had an abnormal content of PSA, and 23/61 (38%) an abnormal gamma-SM. Concentrations of PSA and gamma-SM were significantly correlated (r = 0.68, p less than 0.001). In 20 patients without metastases followed longitudinally, the median concentrations of gamma-SM, PSA, and PAP in the 13 patients who developed bony metastases or showed signs of local spreading of the tumor were 58 ng/mL, 34 ng/mL, and 2.1 U/L, respectively. The corresponding median values in the seven patients who remained clinically stable were 2.5 and 3.9 ng/mL, and 2.3 U/L. We conclude that either PSA or gamma-SM can warn of disease progression when PAP activities are still within normal limits.

scholarly journals IMMUNOHISTOCHEMICAL STUDY OF PROSTATIC ACID PHOSPHATASE AND PROSTATIC SPECIFIC ANTIGEN IN PROSTATIC CARCINOMA

1987 ◽  
Vol 78 (11) ◽  
pp. 1992-1997
Author(s):  
Nobuo Moriyama ◽  
Jun Taniguchi ◽  
Makoto Hara ◽  
Keiko Fukutani ◽  
Hisashi Matsushima ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostatic Carcinoma ◽  
Immunohistochemical Study ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Specific Antigen
Sign in / Sign up

Export Citation Format

Share Document